DOCSLIB.ORG

Symbols Alexian Brothers Health System Index to Nov P

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Symbols Alexian Brothers Health System Index to Nov P Volume 19, Index December 2014 Symbols Alexian Brothers Health System Index to Nov p. 2 Health Care M&A News 1-800-CONTACTS Feb p. 18 A&L Goodbody Apr p. 16, July p. 16 All Care Home Health, LLC Feb p. 17 Each company and orga- A Allergan Inc. Feb p. 10, May p. 1, nization discussed in Health May p. 19, Jun p. 15, July p. 3, Care M&A News, from Janu- Abbott Labs July p. 3, Aug p. 17, July p. 10, Sept p. 16, Oct p. 3, ary through December 2014, Dec p. 4 Nov p. 1, Dec p. 4, Dec p. 16, is listed alphabetically here. AbbVie Inc. July p. 3, July p. 16, Dec p. 19 References are typically to Aug p. 9, Oct p. 2, Oct p. 16, Allscripts Feb p. 2, Apr p. 10 the first occurrence of the Nov p. 19, Dec p. 2 AllSpire Health Partners Nov p. 2 company’s or organiza- ABL, Inc. Aug p. 18 All Staffing Services Jan p. 17 tion’s name in the pertinent Acadia Healthcare Company Feb p. 16, Almost Family, Inc. Apr p. 16 issue; further discussion July p. 17, Oct p. 17, Nov p. 17 ALN Medical Management, LLC may follow later in the text Accelera Innovations, Inc. Jan p. 17 Accelrys, Inc. Jan p. 15 Feb p. 8 but is not indicated here. AccessClosure, Inc. May p. 15 Alta Partners Jun p. 16 Achillion Pharmaceuticals July p. 17 Altos Solutions, Inc. Jun p. 15 References are sorted by Actavis (Foshan) Pharmaceuticals Co. Alvogen Pharma US, Inc. Jan p. 10 the month and page number Ltd. Feb p. 15, Mar p. 2 Amarchand & Mangaldas & Suresh A. of the issue in which the Actavis plc Jan p. 10, Jan p. 16, Shroff & Co. May p. 17 company appears, e.g., Apr Feb p. 15, Mar p. 1, Mar p. 10, American CareSource July p. 1 p. 9 stands for page 9 in the Apr p. 3, Apr p. 19, May p. 17, American HealthTech Feb p. 2 April 2014 issue. July p. 10, Oct p. 3, Oct p. 16, American Realty Capital Jan p. 10 Dec p. 16, Dec. p. 19 American Realty Capital Healthcare Trust Please Note Adage Capital Management Jun p. 16 May p. 18, July p. 18, July p. 19 ADCS Clinics Oct p. 18 American Well Sept p. 4 The various companies Adroscoggin Valley Hospital Nov p. 2 AmeriDoc Sept p. 4 and organizations that are Aduro BioTech, Inc. Jun p. 10 Amgen May p. 10 cited in the “Deal Sum- Advanced Dermatology & Cosmetic Amkai Solutions Feb p. 2 maries” of each monthly Surgery Oct p. 18 Amsurg Corp. Jun p. 1, Jun p. 19, issue are not included here. Adventist Health Sept p. 17, Nov p. 2 Aug p. 1 Instead, reference should be Adventist Midwest Health Nov p. 2 AnaptysisBio, Inc. Apr p. 8 made to the four quarterly Advocate Health Care Oct p. 17 AOP Orphan Pharmaceuticals Mar p. 7 supplements, The Health Advocate NorthShore Health Partners Apax Partners, LP Oct p. 15 Care M&A Report, which Oct p. 17 Apex Affinity Jan p. 10 discuss the individual deals Aetna Sept p. 1, Sept p. 4, Sept p. 18, Apple Inc. Mar p. 15, Sept p. 1 in greater depth. Each quar- Oct p. 15, Dec p. 15 Aptalis Pharma Mar p. 1 terly report comes with its AEW Capital Management Feb p. 17, Aptiv Solutions Apr p. 18 own company index. Apr p. 17 Aragon Pharmaceuticals Aug p. 9 AEW Partners VII, LP Feb p. 17 Argenta Apr p. 18 Agility Health Inc. Jun p. 18 ArmaGen Aug p. 9 Akorn, Inc. May p. 17, Jun p. 16 ArthroCare Corp. Mar p. 15, May p. 2, Albany Molecular Research, Inc. Dec p. 2 Apr p. 18 Arthur Cox May p. 16, July p. 16 Alere Health Nov p. 18 Ascension Health Feb p. 17, Aug p. 4, Alere Inc. Nov p. 18 Sept p. 10, Sept p. 17, Nov p. 17 www.healthcaremanda.com Page 2 Health Care M&A News December 2014 AstraZeneca plc Jan p. 10, Jan p. 16, Feb p. 10, Mar p. 2, Barclays Mar p. 18, May p. 16, Jun p. 18 Mar p. 7, May p. 1, May p. 19, Jun p. 15, July p. 3, Bass, Berry & Sims PLC Jun p. 18 Aug p. 17, Aug p. 19, Sept p. 16, July p. 10, Oct p. 3, Bausch + Lomb Holdings Mar p. 3 Nov p. 1, Dec p. 4, Dec p. 15 Baxter Healthcare Corp. Nov p. 16 At Home Health Services, LLC Jan p. 17 Baxter International May p. 10 ATI Physical Therapy Holdings LLC Jan p. 18 Bayer AG Jan p. 10, May p. 1, Jun p. 10, July p. 10, Dec p. 4 ATLAS Medical Services Aug p. 18 Baylor, Scott & White Nov p. 3 Audax Health Solutions, Inc. Mar p. 10 BD Nov p. 16, Dec p. 3 Aurobindo Pharma, Ltd. Feb p. 15, Mar p. 2 Beaumont Health System July p. 17 Auxilium Pharmaceuticals Nov p. 16 Becton Jan p. 15 AviaraMD Feb p. 3 Behavioral Health Care Associates, Ltd. Jan p. 17 Aviv REIT, Inc. Jan p. 10, Jan p. 17, Jun p. 17, Nov p. 17, Behavioral Health Corp. Dec p. 10 Dec p. 17 Benesch Jun p. 1 Axium Pharmacy Holdings Jun p. 2 Berchtold Holding, AG May p. 2 BerkeryNoyes Feb p. 2 B Biodel Jan p. 15 Bain Capital Sept p. 10 BioFocus Apr p. 18 Bain Capital Ventures Feb p. 3 BioMarin Pharmaceutical, Inc. Dec p. 15 BakerHostetler LLP Jan p. 15 BioMerieux Apr p. 15 Baker & McKenzie LLP Mar p. 17 Biomet, Inc. May p. 1, May p. 15, Dec p. 2 Balfour Senior Living Apr p. 17 Bio-Reference Labs Jan p. 2 Bank Leumi Mar p. 17 BioScrip, Inc. Mar p. 17 BioServe Biotechnologies Pvt. Ltd. July p. 9 Biotech International Feb p. 14, May p. 2 Health Care M&A News BioTelemetry Mar p. 15 ISSN#: 1091-9716 Bioventus Mar p. 10 Published Monthly by: Blackstone Group, The Feb p. 8, May p. 3, Dec p. 2 Irving Levin Associates, Inc. Blue Cross of Illinois Nov p. 3 268-1/2 Main Avenue Blue Cross of Northeastern Pennsylvania Mar p. 18 Norwalk, CT 06851 BofA Merrill Lynch Jan p. 15, May p. 17, Jun p. 15, 800-248-1668 (Phone) Jun p. 18, July p. 17, Aug p. 16, Sept p. 17 203-846-8300 (Fax) Boston Scientific Corp. Jun p. 15 [email protected] Botsford Health Care July p. 17 www.healthcaremanda.com Bridgepoint Development Capital Jan p. 18 Bristol-Myers Squibb Jan p. 16, Feb p. 10, Apr p. 8, July p. 17, Nov p. 16 Publisher: Eleanor B. Meredith Bristol-Myers Squibb Company May p. 14 Managing Editor: Stephen M. Monroe Brookdale Senior Living Mar p. 1 Editor: Lisa E. Phillips bswift Dec p. 15 Advertising: Jeanne Aloi Burke Warren McKay and Serritella PC Apr p. 16 C Annual Subscription Rate: $2,497 Includes 50 weekly email bulletins, Cabell Huntington Hospital Nov p. 2 four quarterly supplements and special database access Cadence Pharmaceuticals, Inc. Mar p. 16 Cain Brothers & Co. LLC Feb p. 2, Mar p. 17, Sept p. 2, © Copyright 2014 Irving Levin Associates, Inc. Nov p. 2 All rights reserved. Reproduction or quotation in whole Caisse de Depot et Placement du Quebec Apr p. 17 or part without permission is forbidden. Caldwell County Hospital Home Health Agency Apr p. 16 Caldwell Medical Center Apr p. 16 This publication is not a complete analysis of every material fact regarding any company, industry or security. Opinions expressed Calfee, Halter & Griswold LLP Aug p. 16 are subject to change without notice. Statements of fact have been California Mission Inn Jun p. 17 obtained from sources considered reliable but no representation is Cancer Genetics, Inc. July p. 9 made as to their completeness or accuracy. POSTMASTER: Please Cangene bioPharma, Inc. Jan p. 15 send address changes to The Health Care M&A Monthly, 268-1/2 Cangene Corporation Jan p. 15 Main Avenue, Norwalk, CT 06851. Cangene Plasma Resources Jan p. 15 Capario July p. 15 www.healthcaremanda.com December 2014 Health Care M&A News Page 3 Capela Jan p. 3 Collab Health May p. 18 Capella Healthcare Dec p. 16 Colorado Springs Health Partners Nov p. 18 Capital Health Group Feb p. 17 CombinatoRx Oct p. 15 Capital Senior Living Corp. Jan p. 17 Comcast Sept p. 4 CAP Medical Group Apr p. 18 Community Health Systems, Inc. Jan p. 3, Jan p. 17, Cardinal Care Management Jan p. 17 Feb p. 17, Mar p. 8, Aug p. 18, Sept p. 10, Dec p. 10, Cardinal Health May p. 15 Dec p. 16 Cardiocom Sept p. 4 Comvest Partners Apr p. 18 CardioMEMS Jun p. 15, Sept p. 3 Concentra July p. 2 CardioNet, Inc. Mar p. 15 Concordia Healthcare July p. 3 CareFusion Nov p. 16, Dec p. 3 Conemaugh Health System Sept p. 17 Caring Brands International Oct p. 17 Connecticut Hospital Association Aug p. 10 Carlyle Group, L.C., The Feb p. 8 Consult A Doctor Sept p. 4 Carnahan Group, The Jan p. 3 Cooley LLP Apr p. 15, Jun p. 15 Carolina Pines Regional Medical Center Dec p. 16 Cosmo Pharmaceuticals S.p.A. Sept p. 16, Oct p. 2, Dec p. Carondelet Health Nov p. 17 16 Casas Adobes Post-Acute Rehab Center Jun p. 17 Cosmo Technologies Sept p. 16, Oct p.
Load more

Recommended publications
  • Preclinical Development & IND Filing: Nuts, Bolts, Best Practices
    “Preclinical Development & IND Filing: Nuts, Bolts, Best Practices and Regulatory Aspects.” Speakers: Amit Kalgutkar (Pfizer), Chandra Prakash (Agios), Sanjeev Thohan (Novartis), Li- Chun Wang (Takeda), Wei Yin (Biogen) Organizers: Sanjeev Thohan and Chandra Prakash Date: 6/29/2017 Time: 8:30 am – 5.00 pm Location: Boston/Cambridge Area: Marriott Kendall Square, 50 Broadway, Cambridge MA 02142 Fees: $175 - Regular (before June 1st, 2017), $225 - Regular (after June 1st, 2017); $125 - Unemployed & Academic; $2000 - Major Sponsorship; $475 - Vendor Show Registration: www.PBSS.org Workshop Description: An investigational new drug application (IND) is an important milestone that marks the entry of a molecule into clinical development. Knowing the objectives, expectations and processes of assembling an IND is a key to not only successful filing, but also a promising clinical development path forward. Often there are cases where too many of our “nice-to-have” studies crowd the package at the expense of critical study needs/issues. This can lead to significant delays in clinical developments with back-and-forth of Q&A sessions both internally and with regulatory agencies. As we have seen, the regulatory landscape is changing as rapidly as the industry innovates into new therapeutic modalities. Therefore, it is critical to keep up to date on regulatory requirements and the industry’s best practices in different aspects of the IND: non- clinical safety, PK, CMC, and clinical plans. In this workshop, our speakers who bring years of experience with multiple successful IND filings, will discuss systematically the preclinical studies required for small molecule IND’s as well as the nuts and bolts of putting together a high–quality IND package.
    [Show full text]
  • Welcome to the Governance Institute's E
    Volume 11, No. 5, September 2014 Welcome to The Governance Institute’s E-Briefings! This newsletter is designed to inform you about new research and expert opinions in the area of hospital and health system governance, as well as to update you on services and events at The Governance Institute. Please note that you are receiving this newsletter because you are a Governance Institute member or expressed interest at one of our conferences. The Rise of the Hospital Joint Venture By Barry Sagraves, Juniper Advisory, and Ken Marlow, Waller This article is the first in a series examining the advantages of joint ventures, the process of developing a joint venture, and expected trends related to these transactions. Since the enactment of the Affordable Care Act in partners that complement and enhance its 2010, more and more hospitals and health systems operations, capitalization, compliance, and quality have entered into some sort of affiliation, whether functions. Exploring a range of joint venture through acquisition, membership substitution, joint alternatives has been found by many systems to be venture, or clinical affiliation. This trend is a result a “best of both worlds” approach—combining the of the mounting pressures hospitals and health installed market presence and reputation of a non- systems face in the current healthcare profit system with the scale, access to capital, and environment. Yet, fundamental change in the management expertise of an investor-owned makeup of the hospital market also paves way for company. innovation, which includes new ways that organizations may partner to confront these Most hospital and health system boards are aware challenges.
    [Show full text]
  • Healthcare & Life Sciences Group
    HEALTHCARE & LIFE SCIENCES GROUP 2 1 Healthcare and life sciences clients have long turned to S&C for help succeeding in today’s rapidly changing business environment. Large and mid-size, public and private, throughout their lifecycles, these companies rely on our multi-disciplinary, global team to address their most complex legal and business challenges and reach their strategic goals. Sector expertise: We offer unrivaled OUR CLIENTS GET… knowledge of the healthcare and life sciences industries, our clients’ businesses and the sector-specific competitive pressures bearing down on them. Sullivan & Cromwell’s Healthcare and Life Sciences Group has negotiated complex transactions and resolved high-stakes disputes for almost three decades. Today, it possesses an unparalleled grasp of these sectors and a practical understanding of the commercial realities underlying them. We position our clients to succeed through it all. The Firm represents international clients in the following healthcare sectors: Pharmaceuticals and Life Sciences Medtech Health Insurers Healthcare Services 2 Legal expertise: Clients come to us An integrated, global team: for the high-quality counsel and hands-on We’re a core group of dedicated healthcare representation we offer across multiple advisers across our 13 offices on four legal specialties, to successfully execute continents with a strong track record of their most important deals and resolve the sector’s most significant transactions critical disputes. We can execute any type and litigation matters, supported by all of transaction in any economic climate or the resources of an integrated, global firm. geographic region. Our experience in this We’re grateful to our clients for trusting sector includes: us with their future, and we’ll continue to help them position themselves for growth M&A and success in this exciting and ever- Corporate finance changing industry.
    [Show full text]
  • NASDAQ Stock Market
    Nasdaq Stock Market Friday, December 28, 2018 Name Symbol Close 1st Constitution Bancorp FCCY 19.75 1st Source SRCE 40.25 2U TWOU 48.31 21st Century Fox Cl A FOXA 47.97 21st Century Fox Cl B FOX 47.62 21Vianet Group ADR VNET 8.63 51job ADR JOBS 61.7 111 ADR YI 6.05 360 Finance ADR QFIN 15.74 1347 Property Insurance Holdings PIH 4.05 1-800-FLOWERS.COM Cl A FLWS 11.92 AAON AAON 34.85 Abiomed ABMD 318.17 Acacia Communications ACIA 37.69 Acacia Research - Acacia ACTG 3 Technologies Acadia Healthcare ACHC 25.56 ACADIA Pharmaceuticals ACAD 15.65 Acceleron Pharma XLRN 44.13 Access National ANCX 21.31 Accuray ARAY 3.45 AcelRx Pharmaceuticals ACRX 2.34 Aceto ACET 0.82 Achaogen AKAO 1.31 Achillion Pharmaceuticals ACHN 1.48 AC Immune ACIU 9.78 ACI Worldwide ACIW 27.25 Aclaris Therapeutics ACRS 7.31 ACM Research Cl A ACMR 10.47 Acorda Therapeutics ACOR 14.98 Activision Blizzard ATVI 46.8 Adamas Pharmaceuticals ADMS 8.45 Adaptimmune Therapeutics ADR ADAP 5.15 Addus HomeCare ADUS 67.27 ADDvantage Technologies Group AEY 1.43 Adobe ADBE 223.13 Adtran ADTN 10.82 Aduro Biotech ADRO 2.65 Advanced Emissions Solutions ADES 10.07 Advanced Energy Industries AEIS 42.71 Advanced Micro Devices AMD 17.82 Advaxis ADXS 0.19 Adverum Biotechnologies ADVM 3.2 Aegion AEGN 16.24 Aeglea BioTherapeutics AGLE 7.67 Aemetis AMTX 0.57 Aerie Pharmaceuticals AERI 35.52 AeroVironment AVAV 67.57 Aevi Genomic Medicine GNMX 0.67 Affimed AFMD 3.11 Agile Therapeutics AGRX 0.61 Agilysys AGYS 14.59 Agios Pharmaceuticals AGIO 45.3 AGNC Investment AGNC 17.73 AgroFresh Solutions AGFS 3.85
    [Show full text]
  • Employment Report
    CAREER MANAGEMENT CENTER Employment Report “One of the most important things we do is to connect companies with the right individuals, groups and resources at Kellogg — students, faculty, alumni and the administration. That’s when we 2009 all realize the full value of creating and sustaining strong relationships.” Table of Contents 4 Class of 2009 Profile 5 Demographic Information: Class of 2009 5 Base Salary Acceptances by Work Experience 5 Base Salary Acceptances by Undergraduate Degree 5 Base Salary Acceptances by Age 5 Base Salary Acceptances by Gender 5 Base Salary Acceptances by Geographic Distribution 6 Major Industries Chosen by Graduates, 2005-2009 6 Class of 2009 Graduate Base Salary Acceptances by Industry 7 Major Functions Chosen by Graduates, 2005-2009 7 Class of 2009 Graduate Base Salary Acceptances by Function 8 Major Employers 9 Graduate Sign-On Bonus by Industry Group 9 Graduate Sign-On Bonus by Functional Group 10 Corporate Recruiters 11 Job Acceptances: Class of 2009 by Company 15 Job Acceptances: Class of 2009 by Student 15 Two-Year MBA & JD-MBA students 27 One-Year MBA students 29 MMM students 30 Part-Time MBA students 33 Major Industries Chosen by Summer Interns, 2005-2009 33 Class of 2010 Summer Intern Salary Acceptances by Industry 34 Major Functions Chosen by Summer Interns, 2005-2009 34 Class of 2010 Summer Intern Salary Acceptances by Function 35 Major Summer Intern Employers 36 Summer Acceptances: Class of 2010 by Company 41 Summer Acceptances: Class of 2010 by Student 41 Two-Year MBA & JD-MBA students 54 MMM students 57 Kellogg Corporate Affiliates 58 Career Management Center Staff The power of collaboration Cover quote: Roxanne Hori, Assistant Dean and Director, Career Management Center Kellogg School of Management 1 he Kellogg School of Management at Companies that sustain relationships with the Kellogg Northwestern University is well known for its School also benefit from other mutually rewarding emphasis on collaboration and teamwork inside opportunities and programs.
    [Show full text]
  • Stamford Therapeutics Consortium Consortiapedia.Fastercures.Org
    Stamford Therapeutics Consortium consortiapedia.fastercures.org Stamford Therapeutics Consortium consortiapedia.fastercures.org/consortia/stamford-therapeutics-consortium/ Research Areas At a Glance Status: Active Consortium Tool Development Year Launched: 1994 Clinical Trial Initiating Organization: Dr. Paul Dalgin Data-Sharing Enabler Initiator Type: Industry Location: North America DevelopmentProduct Drugs Abstract Stamford Therapeutics Consortium (STC) is a privately owned and operated clinical research site specializing in phase II, III, and IV clinical trials for the pharmaceutical and biotechnology industries. STC has a strong working relationship with a cardiology group, a large multispecialty medical practice, and a team of physicians who serve as sub-investigators for many of its clinical trials. STC maintains a significant presence in research for the treatment of osteoarthritis and rheumatoid arthritis, while continuing to expand its research into new therapeutic areas. Year after year STC's list of specialties grows to accommodate a growing demand and new innovations in healthcare. With over 15 years of clinical trials operations, STC has conducted more than 350 national and multi-national clinical trials. Mission The company’s sole mission is to conduct the highest quality clinical trials so that new, safe, and effective medications can be developed, researched, and approved for a variety of indications and diseases. Stamford Therapeutics Consortium - consortiapedia.fastercures.org Page 1/4 Stamford Therapeutics Consortium consortiapedia.fastercures.org Consortium History The site was launched in 1994 and has contributed to clinical trials research ever since. Structure & Governance The consortium is governed by their president, medical director, founder, and clinical research coordinators. Patent Engagement STC actively recruits patients from all over Fairfield County, CT and Westchester County, NY.
    [Show full text]
  • Career Destinations Class of 2010
    2010 Post Graduate Survey Report Career Destinations Class of 2010 Career Development Center www.sju.edu/careers January 2011 The Career Development Center is pleased to present Career Destinations – Saint Joseph’s University Class of 2010 , our annual report of the post- graduate activities of this year’s graduates. Data contained in the report was obtained primarily through a Career Development Center survey of January, May and September graduates of Undergraduate Day, Professional and Liberal Studies and Master’s degree program divisions of the university. Each graduate was contacted at least three times between March 2010 and November 2010 through e-mail, mail and/or telephone. Information was also gathered through the Career Development Center’s recruiting program and through university faculty and administrators. Table of Contents Section I: Undergraduate Day Report Pages 2 – 5 Section II: Professional and Liberal Studies Report Pages 8 –9 Section III: Master’s Programs Report Pages 10 – 12 An electronic version of this report can be found on the Career Development Center’s website, www.sju.edu/careers. For more detailed information on graduates of a particular department, please contact me by telephone (610.660.3100) or by e-mail ([email protected]). Best wishes, Melissa Bergin McClory Assistant Director, Career Development Center CAREER DESTINATIONS SAINT JOSEPH ’S UNIVERSITY CLASS OF 2010 Compiled by the Career Development Center – December 2010 THE 2010 UNDERGRADUATE DAY REPORT • Information is based on 566 respondents, 74% of the graduating class. • 92.7% of the respondents are employed and/or pursuing additional education. • Post-graduate year-of-service programs continue to attract SJU graduates in impressive numbers.
    [Show full text]
  • Bristol-Myers Squibb Company [email protected]
    UNITED STATES SECURITIES A ND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 DIVISION OF CORPORATION FINANCE March 1, 2019 Lisa A. Atkins Bristol-Myers Squibb Company [email protected] Re: Bristol-Myers Squibb Company Incoming letter dated December 21, 2018 Dear Ms. Atkins: This letter is in response to your correspondence dated December 21, 2018 concerning the shareholder proposal (the “Proposal”) submitted to Bristol-Myers Squibb Company (the “Company”) by People for the Ethical Treatment of Animals (the “Proponent”) for inclusion in the Company’s proxy materials for its upcoming annual meeting of security holders. We also have received correspondence from the Proponent dated January 3, 2019. Copies of all of the correspondence on which this response is based will be made available on our website at http://www.sec.gov/divisions/corpfin/ cf-noaction/14a-8.shtml. For your reference, a brief discussion of the Division’s informal procedures regarding shareholder proposals is also available at the same website address. Sincerely, M. Hughes Bates Special Counsel Enclosure cc: Jared Goodman PETA Foundation [email protected] March 1, 2019 Response of the Office of Chief Counsel Division of Corporation Finance Re: Bristol-Myers Squibb Company Incoming letter dated December 21, 2018 The Proposal asks the board to implement a policy that it will not fund, conduct or commission use of the “Forced Swim Test.” There appears to be some basis for your view that the Company may exclude the Proposal under rule 14a-8(i)(7), as relating to the Company’s ordinary business operations. In our view, the Proposal micromanages the Company by seeking to impose specific methods for implementing complex policies.
    [Show full text]
  • Second-Quarter Biotech Job Picture
    CAREERS AND RECRUITMENT Second-quarter biotech job picture Michael Francisco n May, Merck (Kenilworth, NJ, USA) announced it would invest $310 investment capital. The first 13 life science companies in residence were Imillion over the next three years to expand two sites in Ireland—a announced, eight of which are focused on therapeutics and drug discov- biologics facility in Brinny, County Cork, and a vaccines and biologics ery: aratinga.bio, Chimeron Bio, Hookipa Biotech, ENB Therapeutics, plant in Carlow Town, County Carlow—with plans to add 330 jobs in Beagle Bioscience, Sevengenes, Gotham Therapeutics and Renovo total. The Carlow facility is a key production site for the cancer drug Pharmaceuticals. Keytruda (pembrolizumab), which was recently approved by the US And Lexington, Massachusetts–based Agenus said it will shutter its Food and Drug Administration. Just last year, the drugmaker said it site in Basel, Switzerland, and consolidate operations to Cambridge, would add 110 jobs at its plant in Carlow and another 50 positions to UK, and Lexington, as well as focus on its manufacturing operations its operations in Cork. in Berkeley, California. The company will reduce head count by about Last month saw the opening of Alexandria LaunchLabs in the 50 employees. Alexandria Center for Life Science in New York City, as part of a Advertised biotech and pharmaceutical sector jobs in the job data- nearly $1.2-billion joint effort by the city and state of New York to spur bases tracked by Nature Biotechnology during the second quarter of development in the life sciences. LaunchLabs is designed to provide 2017 are shown in Tables 1 and 2.
    [Show full text]
  • Healthcare Fraud & Abuse Review 2017
    HEALTHCARE FRAUD & ABUSE REVIEW 2017 i | BASS, BERRY & SIMS HEALTHCARE FRAUD & ABUSE REVIEW 2017 1. A LOOK BACK…A LOOK AHEAD 4. NOTEWORTHY SETTLEMENTS 7. ISSUES TO WATCH 12. FALSE CLAIMS ACT UPDATE 37. STARK LAW/ANTI-KICKBACK STATUTE 40. PHARMACEUTICAL AND MEDICAL DEVICE DEVELOPMENTS 42. APPENDIX – 2017 NOTABLE SETTLEMENTS Hospitals and Health Systems Managed Care/Insurance Hospice Laboratory, Pathology, Radiology and Diagnostics Home Health Specialty Care and Other Provider Entities SNFs and Nursing Homes Individual Providers Pharmaceutical and Device Miscellaneous/Non-Providers Pharmacy Services 70. ABOUT BASS, BERRY & SIMS General (HHS-OIG), along with federal and state law enforcement entities, including 30 Medicaid Fraud Control Units, charged more than 400 defendants, including 115 healthcare professionals, A LOOK BACK… in 41 federal districts for allegedly participating in fraudulent healthcare arrangements resulting in over $1.3 billion in false claims.6 A LOOK AHEAD Occurring in the context of combatting the opioid crisis, the takedown focused on individuals allegedly involved in fraudulent billing of Medicare, Medicaid and TRICARE for medically While the uncertainty associated with legislative efforts to repeal unnecessary prescription and compounded drugs that were not actually purchased or distributed to patients covered by a federal healthcare program. In total, more than 120 the Patient Protection and Affordable Care Act (PPACA) dominated defendants, including physicians, were charged in connection with prescribing and distributing most of the headlines for the healthcare industry last year, it was opioids and narcotics. Nearly 300 individuals—including physicians, nurses and pharmacists— mostly business as usual for the government’s healthcare fraud received exclusion notices from HHS-OIG barring future participation in federal healthcare 7 enforcement efforts.
    [Show full text]
  • JMP Securities Healthcare Conference to Be Held in New York
    JMP Securities Healthcare Conference to Be Held in New York SAN FRANCISCO, Oct 01, 2008 (BUSINESS WIRE) -- JMP Group Inc. (NYSE:JMP), an investment banking and alternative asset management firm, announced today that its broker-dealer subsidiary, JMPSecurities, will host the third annual JMP Securities Healthcare Focus Conference at Le Parker Meridien in New York on Monday and Tuesday, October 6 and 7, 2008. The two-day conference will feature presentations by senior executives of nearly 90 public and private companies in the biotechnology, medical devices and healthcare services industries before an audience of institutional investors and financial sponsors. For additional details or to register to attend the event, visit www.jmpsecurities.com/about/events.html or www.twstevent.com/jmp.html. Companies scheduled to present as of September 30, 2008; subject to change: A.D.A.M., Inc. ACADIA Pharmaceuticals Inc. Acceleron Pharma, Inc. Achillion Pharmaceuticals, Inc. Alexza Pharmaceuticals, Inc. Allos Therapeutics, Inc. Allscripts Healthcare Solutions, Inc. Alnylam Pharmaceuticals, Inc. American CareSource Holdings, Inc. Anadys Pharmaceuticals, Inc. ARCA biopharma, Inc. Ardea Biosciences, Inc. athenahealth Inc. AtriCure, Inc. AVEO Pharmaceuticals, Inc. AVI BioPharma, Inc. BioCryst Pharmaceuticals, Inc. C. R. Bard, Inc. Cadence Pharmaceuticals, Inc. Celera Corporation Celgene Corporation Celleration, Inc. Cerus Corporation Chem Rx Corporation Concert Pharmaceuticals, Inc. Corcept Therapeutics Incorporated Cypress Bioscience, Inc. Cytokinetics, Incorporated DexCom, Inc. DiagnoCure Inc. Dialysis Corporation of America Echo Therapeutics, Inc. Eclipsys Corp. Enanta Pharmaceuticals, Inc. Endocare Inc. Exelixis, Inc. EyeGate Pharmaceuticals, Inc. Genomic Health, Inc. Given Imaging, Ltd. HeartWare Limited Horizon Therapeutics, Inc. Human Genome Sciences, Inc. HydroCision, Inc. Idenix Pharmaceuticals, Inc. Idera Pharmaceuticals, Inc.
    [Show full text]
  • Local Laboratory Testing of Germline BRCA Mutations Vs. Myriad: a Single-Institution Experience in Korea
    diagnostics Article Local Laboratory Testing of Germline BRCA Mutations vs. Myriad: A Single-Institution Experience in Korea Joohyun Hong 1 , Jiyun Lee 1, Minsuk Kwon 1, Ji-Yeon Kim 1, Jong-Won Kim 2 , Jin Seok Ahn 1, Young-Hyuck Im 1 and Yeon Hee Park 1,* 1 Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea; [email protected] (J.H.); [email protected] (J.L.); [email protected] (M.K.); [email protected] (J.-Y.K.); [email protected] (J.S.A.); [email protected] (Y.-H.I.) 2 Department of Laboratory Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea; [email protected] * Correspondence: [email protected]; Tel.: +82-2-3410-1780 Abstract: Genetic diagnosis for human epidermal growth factor receptor 2-negative metastatic breast cancer patients with the germline BRCA (gBRCA) mutation has been emphasized since the development of polyadenosine diphosphate-ribose polymerase inhibitors. Myriad Genetics, Inc.’s (Salt Lake City, UT, USA) companion diagnostics service is almost exclusively used for genetic testing. The aim of this study was to compare the results of germline BRCA mutation tests returned by a local laboratory and those performed by Myriad. Between April 2014 and February 2018, 31 patients with gBRCA 1/2 mutation test results from both Samsung Medical Center (Seoul, Korea) and Myriad were enrolled. “Discordant: Opposite classification” was observed for only one among 27 (3.7%). Citation: Hong, J.; Lee, J.; Kwon, M.; This discrepancy was due to the detection of a deleterious large genomic rearrangement of BRCA 1 Kim, J.-Y.; Kim, J.-W.; Ahn, J.S.; Im, by Myriad.
    [Show full text]